tpst1120,nivolumab
bms,tempest therapeutics
['rcc,(-irccs),(-srcc),(-urcc)', 'nivo', 'tpst-1120 ', 'nivolumab']
pleased to be a co-investigator of this fih study of the ppar-alpha and fao modulator tpst-1120 +/- nivolumab. deep and durable response in heavily pretreated pt with rcc. oral presentation #asco22 
Medical Oncologist at Miami Cancer Institute: GU Oncology & Phase 1